Genetic profile of advanced thyroid cancers in relation to distant metastasis
- PMID: 32163911
- DOI: 10.1530/ERC-19-0452
Genetic profile of advanced thyroid cancers in relation to distant metastasis
Abstract
Major clinical challenges exist with differentiated thyroid cancers with distant metastases or rare but aggressive types, such as poorly differentiated thyroid carcinomas and anaplastic thyroid carcinomas. The precise characterization of the mutational profile in these advanced thyroid cancers is crucial. Samples were collected from primary tumors and distant metastases of 64 patients with distant metastases from differentiated thyroid cancer, poorly differentiated thyroid carcinoma, or anaplastic thyroid carcinoma. Targeted next-generation sequencing was performed with 50 known thyroid-cancer-related genes. Of the 82 tissues, 63 were from primary tumors and 19 from distant metastases. The most prevalent mutation observed from the primary tumors was TERT promoter mutation (56%), followed by BRAF (41%) and RAS (24%) mutations. TP3 was altered by 11%. Mutations in histone methyltransferases, SWI/SNF subunit-related genes, and PI3K/AKT/mTOR pathway-related genes were present in 42%, 12%, and 22%, respectively. When the mutational status was analyzed in 15 matched pairs of thyroid tumors and their matched distant metastases and one pair of distant metastases with two distinct sites, the concordance was high. A similar frequency of mutations in TERT promoter (58%) and BRAF (42%) as well as histone methyltransferases (37%), SWI/SNF subunits (10%), and PI3K/AKT/mTOR pathway (26%) were noted. The same main, early and late mutations were practically always present in individual primary tumor-metastasis pairs. Enrichment of TERT promoter, BRAF, and RAS mutations were detected in highly advanced thyroid cancers with distant metastasis. The genetic profiles of primary thyroid tumors and their corresponding distant metastases showed a high concordance.
Keywords: advanced thyroid cancer; distant metastasis; genetic profile; next generation sequencing.
Similar articles
-
Highly Concordant Key Genetic Alterations in Primary Tumors and Matched Distant Metastases in Differentiated Thyroid Cancer.Thyroid. 2016 May;26(5):672-82. doi: 10.1089/thy.2015.0527. Thyroid. 2016. PMID: 26971368
-
Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.J Clin Invest. 2016 Mar 1;126(3):1052-66. doi: 10.1172/JCI85271. Epub 2016 Feb 15. J Clin Invest. 2016. PMID: 26878173 Free PMC article.
-
TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease.J Clin Endocrinol Metab. 2017 Jun 1;102(6):1898-1907. doi: 10.1210/jc.2016-2785. J Clin Endocrinol Metab. 2017. PMID: 28323937
-
Genomic Landscape of poorly Differentiated and Anaplastic Thyroid Carcinoma.Endocr Pathol. 2016 Sep;27(3):205-12. doi: 10.1007/s12022-016-9445-4. Endocr Pathol. 2016. PMID: 27372303 Review.
-
Poorly Differentiated Carcinoma of the Thyroid Gland: Current Status and Future Prospects.Thyroid. 2019 Mar;29(3):311-321. doi: 10.1089/thy.2018.0509. Thyroid. 2019. PMID: 30747050 Free PMC article. Review.
Cited by
-
Molecular Genetics of Follicular-Derived Thyroid Cancer.Cancers (Basel). 2021 Mar 7;13(5):1139. doi: 10.3390/cancers13051139. Cancers (Basel). 2021. PMID: 33799953 Free PMC article. Review.
-
Characterizing Genetic Alterations Related to Radioiodine Avidity in Metastatic Thyroid Cancer.J Clin Endocrinol Metab. 2024 Apr 19;109(5):1231-1240. doi: 10.1210/clinem/dgad697. J Clin Endocrinol Metab. 2024. PMID: 38060243 Free PMC article.
-
Loss of Integrase Interactor 1 (INI1) Expression in a Subset of Differentiated Thyroid Cancer.Diagnostics (Basel). 2020 May 5;10(5):280. doi: 10.3390/diagnostics10050280. Diagnostics (Basel). 2020. PMID: 32380731 Free PMC article.
-
2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer.Thyroid. 2021 Mar;31(3):337-386. doi: 10.1089/thy.2020.0944. Thyroid. 2021. PMID: 33728999 Free PMC article.
-
Mutation in Genes Encoding Key Functional Groups Additively Increase Mortality in Patients with BRAFV600E-Mutant Advanced Papillary Thyroid Carcinoma.Cancers (Basel). 2021 Nov 22;13(22):5846. doi: 10.3390/cancers13225846. Cancers (Basel). 2021. PMID: 34831001 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous